XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
Clinical trial NCT05494060 · RECRUITING
Trial details
- NCT number
- NCT05494060
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-16
- Primary completion
- 2024-12-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.